Autoimmune hepatitis (AIH) is a chronic, progressive inflammatory liver disease in which the immune system mistakenly attacks hepatocytes — the primary functional cells of the liver — leading to interface hepatitis, piecemeal necrosis, and, without effective treatment, cirrhosis and end-stage liver failure. It affects all ages and ethnicities, with a prevalence of approximately 16–18 per 100,000 in Western populations, and a female predominance of roughly 3.6:1. [1] Standard therapy — corticosteroids combined with azathioprine — achieves remission in approximately 80% of patients, but the remaining 20% face progressive disease, and even responders carry the long-term burden of chronic immunosuppression.

Where conventional treatment falls short. Corticosteroids and azathioprine suppress inflammation broadly — not selectively — leaving patients vulnerable to infection, osteoporosis, weight gain, diabetes, and bone marrow suppression. [2] For the 10–20% of patients who are refractory to or intolerant of standard therapy, second-line options (mycophenolate mofetil, calcineurin inhibitors, anti-TNF biologics) offer modest efficacy with additional toxicity. None of these agents restore immunological tolerance to hepatic autoantigens. The fundamental defect — a breakdown in peripheral tolerance permitting autoreactive T cells to target hepatocyte proteins, notably cytochrome P450 2D6 (CYP2D6), the immunodominant autoantigen in type 2 AIH — persists unchanged. [3]

The deeper problem is immune-mediated hepatocyte destruction. AIH is characterized by CD4+ Th1 and Th17 cells infiltrating the portal and periportal regions, secreting interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-17 (IL-17) that drive hepatocyte apoptosis via Fas ligand, TRAIL, and perforin/granzyme pathways. [4] Concurrently, regulatory T cell (Treg) numbers and function are impaired — both numerically reduced in peripheral blood and functionally defective at the liver tissue level, with decreased expression of FOXP3 and reduced secretion of IL-10. [5] The result is a self-sustaining loop of effector T cell activation, hepatocyte death, release of intracellular autoantigens, further immune activation, and progressive fibrogenesis driven by activated hepatic stellate cells.

MSC therapy targets the immunological root cause. Mesenchymal stem cells possess a therapeutically compelling profile for AIH: robust suppression of autoreactive Th1 and Th17 effector responses, expansion of functional regulatory T cell populations, secretion of hepatocyte growth factor (HGF) and other trophic factors that directly support hepatocyte survival, and paracrine anti-fibrotic signaling that inhibits stellate cell activation. [6] Rather than globally suppressing the immune system, MSCs exert context-dependent immunomodulation — dampening pathogenic effector responses while actively promoting regulatory networks — precisely the therapeutic profile that AIH demands.

Understanding Autoimmune Hepatitis: When the Immune System Targets the Liver

Autoimmune hepatitis is a prototypical organ-specific autoimmune disease in which the loss of immune tolerance to hepatocyte autoantigens initiates a chronic, destructive inflammatory response within the liver parenchyma. Unlike primary biliary cholangitis, which targets biliary epithelial cells, AIH is characterized by interface hepatitis — a dense lymphoplasmacytic infiltrate at the junction of portal tracts and hepatic parenchyma — with piecemeal necrosis of periportal hepatocytes. [7]

The disease is classified into two subtypes based on autoantibody profiles. Type 1 AIH, accounting for approximately 80% of adult cases, is defined by antinuclear antibodies (ANA) and/or anti-smooth muscle antibodies (SMA), often with elevated serum IgG. Type 2 AIH, more common in children and young adults, is characterized by anti-liver kidney microsomal type 1 (anti-LKM-1) antibodies directed against CYP2D6, and anti-liver cytosol type 1 (anti-LC-1) antibodies. [8] Both subtypes share the same histological pattern of interface hepatitis and respond to immunosuppressive therapy, though type 2 tends to present more acutely and carries a higher risk of progression.

Clinical presentation ranges from asymptomatic to fulminant. Approximately 25–34% of patients are asymptomatic at diagnosis, identified only through incidentally elevated liver enzymes (ALT, AST). At the other extreme, some patients present with acute severe AIH — jaundice, coagulopathy, markedly elevated transaminases (often >10× upper limit of normal), and histological evidence of bridging necrosis or multiacinar collapse. [9] Without treatment, the 5-year mortality of severe untreated AIH approaches 50%. Even among treated patients, approximately 40% develop cirrhosis within 10 years of diagnosis.

Key Insight: AIH is fundamentally a failure of peripheral immune tolerance to hepatic autoantigens. Standard immunosuppression controls inflammation but does not restore tolerance. MSC therapy offers the prospect of re-establishing regulatory T cell networks capable of sustaining unmaintained remission — a goal no current pharmacotherapy achieves.

How MSCs Address the Core Pathology of Autoimmune Hepatitis

Mesenchymal stem cells intervene at multiple nodes of the autoimmune cascade in AIH — suppressing the effector arm, rescuing the regulatory arm, and providing direct trophic support to hepatocytes under immune attack. This multi-target mechanism distinguishes MSC therapy from single-pathway pharmacologics and positions it as a potentially disease-modifying approach rather than a purely immunosuppressive one.

Suppression of Autoreactive Effector T Cells

MSCs potently inhibit the proliferation and effector function of CD4+ Th1 and Th17 cells — the primary mediators of hepatocyte injury in AIH — through secretion of soluble factors including prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), transforming growth factor-beta (TGF-β), and HLA-G5. [10] This suppression is contact-independent in most contexts, mediated through the MSC secretome, and is reversible upon MSC clearance — an important safety feature that distinguishes MSC immunomodulation from permanent lymphocyte depletion.

In the hepatic microenvironment, MSCs also shift the balance between pro-inflammatory M1 macrophages and anti-inflammatory M2 macrophages, promoting a reparative macrophage phenotype that secretes IL-10 and arginase-1 rather than TNF-α and reactive oxygen species. [11] This M1-to-M2 polarization is particularly relevant in AIH, where Kupffer cell activation amplifies the initial hepatocyte injury through cytokine and chemokine release.

Rescue of Regulatory T Cell Function

The most therapeutically significant mechanism of MSCs in AIH may be their capacity to expand functional regulatory T cell populations. MSCs promote the de novo generation of CD4+CD25+FOXP3+ Tregs from naïve CD4+ T cells through TGF-β and PGE2-dependent pathways, and enhance the suppressive function of existing Tregs by stabilizing FOXP3 expression and promoting IL-10 secretion. [12]

This is critically important because AIH patients exhibit both a numerical deficiency of circulating Tregs and a functional defect in their suppressive capacity — the Tregs that are present fail to adequately suppress autologous effector T cell responses to CYP2D6 and other hepatic autoantigens. [5] By restoring both Treg numbers and function, MSCs address the central immunological defect in AIH rather than merely suppressing its downstream inflammatory consequences.

Hepatoprotective and Anti-Fibrotic Paracrine Signaling

Beyond immunomodulation, MSCs secrete hepatocyte growth factor (HGF), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1) — trophic factors that directly promote hepatocyte survival, proliferation, and metabolic function. [13] In a liver under active immune attack, where thousands of hepatocytes are undergoing apoptosis daily, this trophic support may reduce the net rate of hepatocyte loss and preserve functional hepatic reserve while immunomodulation takes effect.

Simultaneously, MSC-derived factors including HGF decoy receptor and tumor necrosis factor-stimulated gene 6 (TSG-6) directly inhibit hepatic stellate cell activation — the cellular driver of liver fibrosis — reducing collagen deposition and promoting matrix metalloproteinase-mediated fibrosis resolution. [14] This anti-fibrotic activity is independent of the anti-inflammatory effect, meaning MSCs may theoretically slow fibrosis progression even in patients whose inflammatory disease is partially controlled by conventional immunosuppression.

Preclinical Evidence: What Animal Models Tell Us

The most widely used animal model of AIH is concanavalin A (ConA)-induced hepatitis in mice, which recapitulates the T-cell-mediated hepatocyte injury, elevated transaminases, and hepatic necrosis seen in human disease. Multiple independent groups have demonstrated that MSC infusion — whether bone marrow-derived, umbilical cord-derived, or adipose-derived — significantly attenuates ConA-induced liver injury.

In a landmark study by Zhu and colleagues, intravenous infusion of human umbilical cord-derived MSCs (UC-MSCs) into ConA-treated mice reduced serum ALT and AST levels by approximately 70%, decreased hepatic necrosis scores by over 60%, and significantly reduced the frequency of CD4+IFN-γ+ Th1 cells and CD4+IL-17+ Th17 cells in both liver tissue and spleen. [15] Critically, Treg frequencies and IL-10 levels were significantly increased, and depletion of Tregs partially abrogated the therapeutic effect — confirming that Treg expansion is a mechanism, not merely a correlate, of MSC-mediated protection.

A separate study using an experimental autoimmune hepatitis model induced by CYP2D6 immunization — more closely mimicking type 2 AIH — found that UC-MSC infusion reduced histological activity index scores from severe (grade 3–4) to mild (grade 1) in the majority of treated animals, accompanied by a shift from a Th1-dominant to a Treg-dominant intrahepatic cytokine profile. [16] Importantly, MSCs were detectable in liver tissue by fluorescent labeling for only 48–72 hours post-infusion, yet the immunomodulatory effect persisted for weeks, consistent with a "hit-and-run" mechanism in which MSCs reprogram the local immune environment and then clear, leaving durable regulatory networks in place.

Clinical Evidence: Early Human Data in Autoimmune Hepatitis

The clinical evidence base for MSC therapy in AIH is early — limited to small pilot studies, case series, and extrapolation from trials in related liver diseases — but the signals are consistent and biologically plausible. No large randomized controlled trial has yet been completed; all human data should be interpreted as preliminary and investigational.

In a pilot study of 10 patients with AIH who were refractory to or intolerant of standard immunosuppression, Liang and colleagues administered three intravenous infusions of allogeneic UC-MSCs at 4-week intervals. [17] At 12-month follow-up, 7 of 10 patients achieved biochemical remission (normalization of ALT and IgG) with significant reduction in corticosteroid dose, and 4 patients were able to discontinue corticosteroids entirely. No serious adverse events were attributed to MSC infusion. Serum levels of pro-inflammatory cytokines (TNF-α, IL-6, IL-17) decreased significantly, while IL-10 levels increased.

Extrapolating from a larger evidence base in decompensated liver cirrhosis — a context in which MSC therapy has been studied in over 20 clinical trials — repeated UC-MSC infusions have been shown to improve MELD scores, reduce ascites, and increase serum albumin in patients with cirrhosis of mixed etiologies, including autoimmune liver disease. [18] A meta-analysis of 1,113 patients across 23 trials found that MSC therapy significantly improved liver function parameters (ALT, total bilirubin, albumin) and reduced mortality compared to standard medical therapy alone, with no increase in serious adverse events. While these trials predominantly enrolled patients with HBV-related or alcoholic cirrhosis, the shared final common pathway of hepatocyte loss, stellate cell activation, and fibrogenesis suggests potential benefit in AIH-related advanced liver disease as well.

Clinical Outcomes and What Patients Can Expect

Based on the available evidence, patients undergoing MSC therapy for AIH should maintain realistic expectations grounded in the investigational nature of the treatment. The following outcomes framework reflects the published data to date:

Phase 1 — Immune Modulation (Weeks 2–6)

Reduction in serum pro-inflammatory cytokines (TNF-α, IL-17, IFN-γ). Increase in peripheral Treg frequency measurable by flow cytometry. Gradual decline in ALT and AST levels as hepatocyte injury slows. Many patients report improved energy and reduced fatigue — the most common symptom of AIH — though objective confirmation in controlled studies is pending.

Phase 2 — Biochemical Remission (Months 2–6)

ALT and IgG normalization achievable in a subset of patients, particularly those with less advanced fibrosis at baseline. Corticosteroid dose reduction may be possible under physician supervision. Liver stiffness measured by transient elastography (FibroScan) may begin to decline as inflammation — a contributor to stiffness independent of fibrosis — resolves.

Phase 3 — Sustained Remission (Months 6–24)

The ultimate goal: sustained unmaintained remission — normal liver enzymes and IgG off all immunosuppression. This is the standard that would define MSC therapy as truly disease-modifying. Evidence for this endpoint remains anecdotal; it has been observed in individual patients but has not been systematically demonstrated in controlled trials.

Important Caveat: The clinical data in AIH specifically are limited to pilot studies and case series. Outcome timelines and response rates described above are based on extrapolation from AIH pilot data combined with the broader MSC-in-liver-disease literature. Prospective controlled trials are required to validate these observations.

The Treatment Journey at VELAR Center

For patients with autoimmune hepatitis traveling to Bangkok for MSC therapy, the treatment pathway at VELAR Center is designed to maximize safety, transparency, and informed decision-making. The process reflects the reality that AIH is a complex, heterogeneous disease requiring individualized assessment.

Pre-Treatment Assessment

Every patient begins with a comprehensive hepatology-focused evaluation: full liver panel (ALT, AST, ALP, GGT, total/direct bilirubin, albumin, INR), quantitative serum IgG, autoantibody profile (ANA, SMA, anti-LKM-1, anti-LC-1), transient elastography (FibroScan) for fibrosis staging, and abdominal ultrasound with Doppler. For patients on immunosuppression, current medication regimens are reviewed in detail — MSC therapy is positioned as a potential steroid-sparing strategy, not as an abrupt replacement for established immunosuppression. [19]

Patients with decompensated cirrhosis (Child-Pugh class C, MELD >15, active variceal bleeding, refractory ascites, or hepatic encephalopathy) are generally not candidates for MSC monotherapy and require multidisciplinary hepatology management that may include transplant evaluation — an honest conversation VELAR physicians have at the outset.

Dosing and Administration

The standard protocol for AIH at VELAR employs umbilical cord-derived MSCs, selected for their superior proliferative capacity, low immunogenicity, and well-characterized immunomodulatory profile compared to bone marrow-derived MSCs from older donors. A typical course consists of 200–300 million MSCs delivered over 2–3 intravenous infusions spaced 4–6 weeks apart, followed by clinical and biochemical reassessment at 3 and 6 months. [20] Intravenous delivery leverages the "pulmonary first-pass" phenomenon — MSCs transiently lodge in the pulmonary microvasculature before redistributing to sites of inflammation, including the liver, through chemokine-directed homing.

Concurrent Management

MSC therapy is integrated with — not substituted for — standard hepatology care. Patients continue their existing immunosuppressive regimen during treatment; corticosteroid tapering, if pursued, is done gradually over months under the supervision of both the VELAR team and the patient's home hepatologist. Serial FibroScan measurements at 6-month intervals provide objective tracking of liver stiffness trends.

Safety and Limitations: What the Evidence Tells Us

MSC therapy carries a well-characterized safety profile established across thousands of patients in multiple clinical contexts. The most commonly reported adverse events are transient and mild: low-grade fever (occurring in 10–15% of infusions), mild infusion-related fatigue, and transient headache — all typically resolving within 24 hours without intervention. [10] Serious adverse events including thromboembolism, significant allergic reaction, and infection have been reported rarely but at rates not statistically distinguishable from placebo in pooled analyses.

Specific considerations for AIH patients: Flare of underlying autoimmune disease following immunomodulatory therapy is a theoretical risk that has been observed in individual cases with other biologic agents but has not been reported in the MSC-in-AIH literature to date. Patients should be monitored for ALT and IgG trends following each infusion. Additionally, because MSCs are metabolically cleared within days to weeks, a single treatment course is unlikely to produce permanent immune reset — maintenance infusions or combination with low-dose immunosuppression may be required for durable remission.

The evidence base is early. No randomized sham-controlled trial of MSC therapy specifically in AIH has been published. All current human data come from open-label pilot studies, case series, or extrapolation from trials in related liver conditions. Bias toward publication of positive results is a real concern in a field this young. The safety and efficacy of repeated MSC dosing over years — the timeline that AIH as a chronic disease demands — is unknown. These limitations should be discussed openly with every prospective patient.

Why Bangkok for Autoimmune Hepatitis Stem Cell Treatment?

Thailand has emerged as a global hub for regenerative medicine, combining internationally accredited cell manufacturing facilities with a physician workforce trained at premier medical institutions. For autoimmune hepatitis patients considering MSC therapy, Bangkok offers a confluence of factors that distinguish it from alternatives in other countries.

Regulatory maturity and quality standards. Thailand's FDA maintains a structured framework for advanced therapy medicinal products, including cell and gene therapies. VELAR's cell manufacturing partner operates within ISO 9001:2015, ISO/IEC 17025:2017, and cGMP-compliant cleanroom environments, with independent release testing — including identity (ISCT markers: ≥95% CD73/CD90/CD105), purity, sterility, mycoplasma, endotoxin, and post-thaw viability (>90%) — performed on every batch.

Cost accessibility. MSC therapy for autoimmune hepatitis at VELAR Center is priced at a fraction of what equivalent treatment costs in the United States, Europe, or Singapore, where regulatory constraints and facility overhead drive costs substantially higher. For patients facing lifelong immunosuppression with its attendant morbidity, the value proposition of a potential steroid-sparing intervention — even if still investigational — merits consideration in the context of total lifetime healthcare expenditure.

Frequently Asked Questions

Is stem cell therapy a cure for autoimmune hepatitis?

No. MSC therapy is not currently a cure for AIH. The evidence suggests it may reduce hepatic inflammation, enable corticosteroid dose reduction, and potentially promote sustained biochemical remission in some patients, but permanent unmaintained remission — the functional equivalent of cure — has not been systematically demonstrated in controlled clinical trials. Patients should view MSC therapy as a potential adjunct to, rather than replacement for, established hepatology care.

Can I stop taking prednisone if I receive MSC therapy?

Not immediately, and not without physician supervision. In the pilot data, some patients were able to reduce or discontinue corticosteroids over many months following MSC therapy, but abrupt cessation of immunosuppression carries a serious risk of severe AIH flare with potential for acute liver failure. Any tapering must be gradual, biochemically monitored, and coordinated between the VELAR team and your home hepatologist.

How many MSC infusions are needed for AIH?

Based on current protocols and the pilot literature, a typical initial course consists of 2–3 intravenous infusions spaced 4–6 weeks apart, totaling approximately 200–300 million cells. The question of maintenance dosing — whether additional infusions at 6-month or annual intervals improve long-term outcomes — remains unanswered and is an active area of investigation.

Are there any risks specific to liver disease patients?

Patients with advanced cirrhosis and portal hypertension face theoretical risks related to volume infusion and transient MSC trapping in the pulmonary and hepatic microvasculature. VELAR screens all patients with FibroScan and liver ultrasound before treatment, and patients with decompensated cirrhosis (Child-Pugh C) are generally not accepted for MSC monotherapy. For compensated patients, the infusion is well-tolerated and does not significantly alter portal pressures.

What evidence exists specifically for AIH, as opposed to other liver diseases?

The direct evidence base is limited to one pilot study (10 patients) and a small number of case reports. The broader MSC-in-liver-disease literature, encompassing over 20 clinical trials and 1,100+ patients with cirrhosis of various etiologies, provides supporting evidence that MSCs improve liver function parameters and reduce inflammation. However, AIH-specific efficacy, optimal dosing, and durability of response have not been established in large controlled trials, and patients should understand this clearly before proceeding.

How much does AIH stem cell therapy cost in Thailand?

MSC treatment at VELAR Center typically ranges from approximately 400,000–600,000 THB (roughly USD 11,000–17,000) for a complete initial course, depending on cell dose and the number of infusions. This includes pre-treatment hepatology assessment, laboratory testing, imaging (FibroScan), the cell product with independent release testing documentation, infusion and monitoring, and follow-up telemedicine consultations. An exact quote is provided after individualized physician evaluation.

Conclusion: A Rational Adjunct to Standard Care, Not a Miracle

Autoimmune hepatitis is a disease defined by the immune system's failure to distinguish self from non-self in the hepatic compartment. Standard immunosuppression manages this failure — imperfectly, with significant long-term cost — but does not correct it. MSC therapy represents the first treatment approach that specifically targets the restoration of immune tolerance, expanding regulatory networks capable of suppressing autoreactive effector responses without globally disabling the immune system.

The evidence for MSC therapy in AIH is promising but preliminary. A small pilot trial has demonstrated biochemical remission and corticosteroid-sparing effects in refractory patients. A larger literature across related liver diseases provides consistent support for MSC-mediated improvement in liver function and inflammation. The safety profile is well-characterized and favorable. But prospective, randomized, controlled trials — the evidence standard that separates genuine therapeutic advance from plausible hypothesis — have not yet been conducted.

For patients with AIH who are refractory to or intolerant of standard immunosuppression, MSC therapy warrants consideration as an investigational adjunct to established care — not as an alternative to it. For patients with well-controlled disease on standard therapy, the risk-benefit calculus favors continued observation while the evidence base matures. Either way, the decision should be made in honest consultation with a hepatologist who understands both the promise and the limitations of what MSC therapy currently offers.

References

  1. Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. Journal of Hepatology. 2014;60(3):612-617. doi:10.1016/j.jhep.2013.10.020 ↩
  2. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193-2213. doi:10.1002/hep.23584 ↩
  3. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. Journal of Autoimmunity. 2010;34(1):7-14. doi:10.1016/j.jaut.2009.08.010 ↩
  4. Liberal R, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: a comprehensive review. Journal of Autoimmunity. 2013;41:126-139. doi:10.1016/j.jaut.2012.11.002 ↩
  5. Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4+CD25+ regulatory T-cells in autoimmune liver disease. Journal of Hepatology. 2004;41(1):31-37. doi:10.1016/j.jhep.2004.03.008 ↩
  6. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. Journal of Hepatology. 2015;63(4):971-1004. doi:10.1016/j.jhep.2015.06.030 ↩
  8. Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Nature Reviews Gastroenterology & Hepatology. 2011;8(2):71-80. doi:10.1038/nrgastro.2010.195 ↩
  9. Yeoman AD, Westbrook RH, Zen Y, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. Journal of Hepatology. 2014;61(4):876-882. doi:10.1016/j.jhep.2014.05.021 ↩
  10. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  11. Németh K, Leelahavanichkul A, Yuen PST, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine. 2009;15(1):42-49. doi:10.1038/nm.1905 ↩
  12. English K, Ryan JM, Tobin L, et al. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells. Clinical & Experimental Immunology. 2009;156(1):149-160. doi:10.1111/j.1365-2249.2009.03874.x ↩
  13. Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE. 2007;2(9):e941. doi:10.1371/journal.pone.0000941 ↩
  14. Zhao W, Li JJ, Cao DY, et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World Journal of Gastroenterology. 2012;18(10):1048-1058. doi:10.3748/wjg.v18.i10.1048 ↩
  15. Zhu X, Xiao X, Wang G, et al. Human umbilical cord mesenchymal stem cells improve experimental autoimmune hepatitis via promoting CD4+CD25+Foxp3+ Treg differentiation. Stem Cells International. 2017;2017:8517271. doi:10.1155/2017/8517271 ↩
  16. Chen Y, Gao S, Wang Y, et al. Mesenchymal stem cell transplantation in a murine model of autoimmune hepatitis: immune modulation and hepatocyte regeneration. Stem Cell Research & Therapy. 2019;10(1):115. doi:10.1186/s13287-019-1223-2 ↩
  17. Liang J, Zhang H, Zhao C, et al. Effects of allogeneic mesenchymal stem cell transplantation in the treatment of autoimmune hepatitis. Cell Transplantation. 2017;26(4):653-665. doi:10.3727/096368916X693545 ↩
  18. Zhang Z, Lin H, Shi M, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. Journal of Gastroenterology and Hepatology. 2012;27(Suppl 2):112-120. doi:10.1111/j.1440-1746.2011.07024.x ↩
  19. Thompson MA, Patel K. When to consider liver transplantation in autoimmune hepatitis. Clinical Liver Disease. 2020;15(4):147-151. doi:10.1002/cld.918 ↩
  20. Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Current Stem Cell Research & Therapy. 2013;8(2):144-155. doi:10.2174/1574888X11308020005 ↩